相关实验视频

Updated: Jun 26, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

在激素受体阳性,HER2阴性晚期乳腺癌中的HS-10352:一期剂量升级试验

Quchang Ouyang¹, Ying Wang², Jian Zhang³

¹Department of Breast Medicine, Hunan Cancer Center, Changsha, Hunan, China.

Cancer medicine

|December 1, 2023

概括

一种新型PI3Kα抑制剂,HS-10352,在晚期激素受体阳性,HER2阴性乳腺癌患者中表现出良好的耐受性和初步抗瘤活性,特别是那些具有PIK3CA突变的患者.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

大约40%的晚期乳腺癌 (ABC) 患者具有激素受体 (HR) 阳性和人体表皮生长因子受体2 (HER2) 阴性状态,具有PIK3CA突变.
在HR+/HER2- ABC中,PIK3CA突变是关键的驱动因素,代表了新疗法的目标.

研究的目的:

评估选择性PI3Kα抑制剂HS-10352的安全性,耐受性,药理动力学和初步抗瘤活性.
为了确定HS-10352的最大耐受剂量 (MTD) 和剂量限制毒性 (DLT) 在这个患者群体中.

主要方法:

一个第一阶段的剂量升级试验,涉及18名HR+/HER2-ABC的女性患者.
口服HS-10352每天一次 (QD) 剂量为2,4,6和8毫克.
主要终点包括DLT和MTD评估.

主要成果:

HS-10352的MTD被确定为6毫克QD,高血糖是主要的DLT.
与治疗相关的常见不良事件包括高血糖症 (88.9%) 和体重减轻 (61.3%).
在6毫克QD组中,66.7%的患者实现了部分反应 (PR),16.7%患有稳定疾病 (SD);特别是75%的PIK3CA突变患者实现了PR.

结论:

在HR+/HER2-ABC患者中,HS-10352在6毫克QD的剂量被很好地容忍.
HS-10352表现出有希望的初步抗瘤活性,特别是在患有PIK3CA突变瘤的患者中.
这些发现支持HS-10352在晚期乳腺癌治疗中继续进行临床开发.

关键词:

在HS-10352中使用.乳腺癌乳腺癌乳腺癌剂量升级剂量的升级.激素受体激素受体是什么人类表皮生长因子受体2

更多相关视频

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...